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Background: Hypothermia-treated and intubated infants with moderate or severe hypoxic-ischemic enceph-
alopathy (HIE) usually receive morphine for sedation and analgesia (SA) during therapeutic hypothermia
(TH) and endotracheal ventilation. Altered drug pharmacokinetics in this population increases the risk of
drug accumulation. Opioids are neurotoxic in preterm infants. In term infants undergoing TH, the long-term
effects of morphine exposure are unknown. We examined the effect of opioid administration during TH on
neurodevelopmental outcome and time to extubation after sedation ended.
Methods: In this prospectively collected population-based cohort of 282 infants with HIE treated with TH
(20072017), the cumulative opioid dose of morphine and equipotent fentanyl (1060 mg/kg/h) adminis-
tered during the first week of life was calculated. Clinical outcomes and concomitant medications were also
collected. Of 258 survivors, 229 underwent Bayley-3 neurodevelopmental assessments of cognition, lan-
guage and motor function at 1824 months. Multivariate stepwise linear regression analysis was used to
examine the relation between cumulative opioid dose and Bayley-3 scores. Three severity-groups (mild-
moderate-severe) were stratified by early (<6 h) amplitude-integrated electroencephalography (aEEG)
patterns.
Findings: The cumulative dose of opioid administered as SA during TH was median (IQR) 2121 mg/kg (1343,
2741). Time to extubation was independent of SA dose (p > 0.2). There was no significant association
between cumulative SA dose and any of the Bayley-3 domains when analysing the entire cohort or any of the
aEEG severity groups.
Interpretation: Higher cumulative opioid doses in TH-treated infants with HIE was not associated with worse
Bayley-3 scores at 1824 months of age.
Funding: The Bristol cooling program was funded by the Children's Medical Research Charity SPARKS manag-
ing donations for our research from the UK and US, the UK Moulton Foundation, the Lærdal Foundation for
Acute Medicine in Norway and the Norwegian Research Council (JKG).
© 2021 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/)stitute of Basic Medical Scien-
Thoresen).
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Infants with hypoxic-ischaemic encephalopathy (HIE) treated
with therapeutic hypothermia (TH) require sedation and analgesia
(SA) to ameliorate the discomfort and pain from cooling, intubation
and mechanical ventilation [1]. Morphine is the most frequently used
analgesic drug in this population [2]. To date, there are no standard-
ized dosing guidelines for SA during TH. Out of four early randomizedcontrolled cooling trials [36] only the European hypothermia trial
recommended a standard dose of morphine at 100 mg/kg every 4 h
or combined with fentanyl at equipotent doses. There are no cohort
studies with sufficient sample size that have examined the dose-
dependent effect of neonatal morphine exposure on neurodevelop-
mental outcome in term-born asphyxiated infants treated with TH.
Morphine exposure is associated with adverse neurodevelopmen-
tal outcome in preterm and very preterm infants. In very preterm
infants (median gestational weeks (GW) = 27.4), morphine dose
(median cumulative morphine dose 1905 mg/kg) administered from
birth to term-equivalent age was associated with smaller cerebella at
term-equivalent age and poorer motor and cognitive outcomes at 18
Research in context
Evidence before this study
Neonatal hypoxic-ischaemic encephalopathy (HIE) is usually
caused by insufficient cerebral perfusion and oxygen supply
around the time of birth. Infants diagnosed with moderate or
severe HIE are treated with therapeutic hypothermia (TH) for
3 days, which reduces brain injury and improves long-term
outcome. During TH, infants are cooled to 33.5 °C core tempera-
ture and undergo sedation and analgesia (SA) with morphine to
relieve discomfort from cooling and endotracheal ventilation.
There are concerns whether morphine may be harmful to the
term-born injured brain. In preterm infants, prolonged mor-
phine exposure is associated with poor neurodevelopmental
outcomes. In experimental models of HIE, the effects of opioid
exposure on the brain are inconclusive. On one hand, opioids
cause neuronal death in the cerebellum and on the other, they
stimulate microglia-mediated brain repair following injury. In
infants with HIE treated with TH, the long-term effects of mor-
phine exposure in high doses on neurodevelopmental out-
comes are unknown.
Added value of this study
We examined the dose-dependent relationship between opi-
oid-exposure during TH and Bayley-3 developmental scores at
1824 months in 282 infants over an 11-year period. Morphine
was the most commonly used opioid, though 11% of the infants
also received fentanyl. We show an annual increase in the
dose of opioids given due to a change in clinical practice.
Asphyxia severity and the duration of ventilation remained
largely unchanged. Overall, at 1824 months, we found no
adverse effects of morphine exposure in high doses during TH
on neurodevelopmental outcome.
Implications of all the available evidence
We found no adverse effects of continuous morphine and fenta-
nyl delivery on developmental scores at 1824 months. There
was no relation between opioid dose received and time to extu-
bation after rewarming. As data on fentanyl in larger cohorts
are still lacking, we recommend the use of morphine. More reli-
able assessments of stress and discomfort during TH are needed
to support clinical decision-making.
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2 J.K. Gundersen et al. / EClinicalMedicine 00 (2021) 100892months [7]. In the NEOPAIN trial of preterm infants [8], those treated
with morphine had 7% smaller head circumferences and lower body
weights (4%) at school age. Morphine-exposed individuals also
exhibited longer latencies in decision-making, but with no effect on
the intelligence quotient or academic achievement [9]. Neonatal pain
is also potentially harmful to the developing brain. For example, in
very preterm infants (2432 GW), the number of painful procedures
during intensive care correlated with smaller cerebral cortex [10],
cerebellum[11] and subcortical structures [12] at school-age.
Opioid-receptors are widespread in the brain and participate in
regulating neurodevelopment. From our own work, in a global hyp-
oxic-ischaemic model in newborn pigs, lack of SA during 24 h of
post-insult TH completely abolished the neuroprotective effect of
cooling [13]. The cooled unanaesthetised pigs had increased heart
rate (HR) and four times the cortisol levels as a sign of stress, as com-
pared to cooled anaesthetised pigs [14]. SA during TH improved neu-
roprotection in this model. In another study, 24 h of fentanyl infusion
in healthy newborn pigs without HIE induced cell death in the cere-
bellar granular cell layer [15], while other regions were spared [16].Please cite this article as: J.K. Gundersen et al., Morphine and fent
neurodevelopment, EClinicalMedicine (2021), https://doi.org/10.1016/j.eDifferences between species in developmental milestones and opioid
receptor type and distribution makes it challenging to assess opioid
neurotoxicity in human newborns compared to other species.
The pharmacokinetics and pharmacodynamics of opioids and
their metabolites are temperature-dependent. In asphyxiated infants
treated with TH, morphine metabolism is reduced because of cooling
and hypoxic-ischaemic liver and renal injury [17,18]. Prolonged SA
during TH may lead to toxic accumulation of the sedative and its
metabolites, as reported from a single site in the TOBY trial [19]. Mor-
phine receptor affinity is reduced by 80% at 30 °C as compared to 37 °
C in the guinea pig ilium [20]. If this is translatable to cooled infants,
3.5 °C reduction in body temperature would lower the potency of
morphine by 40%.
The long-term effects into childhood and adolescence of mor-
phine exposure in term-born cooled asphyxiated infants are
unknown. Given the adverse effects of SA on the developing brain in
experimental studies and preterm infants, we hypothesized that
higher cumulative SA doses during cooling and rewarming will
impair cognitive ability and language in late infancy. We investigated
whether there is a dose-dependent effect of SA on Bayley-3 scores at
1824 months in a cohort of 282 cooled asphyxiated infants. During
normothermia, high doses of opioids are a respiratory depressant.




We analysed a prospectively collected population-based cohort of
361 (suppl. 1) term infants (GW 36 weeks) born between 01/01/
2007 and 31/12/2019. Ethical approval was obtained from the NHS
South West-Central Bristol Research Ethics Committee (CH/2009/
3091), the Health Research Authority and was sponsored by the Uni-
versity of Bristol. The anonymized cohort study had waiver of con-
sent. Infants were either inborn or transferred to St. Michael’s
Hospital, Bristol, UK for whole-body cooling (active cooling to 33.5 °C
for 72 h with servo-controlled equipment, CritiCool, Mennen Medi-
cal, Israel). St. Michael’s hospital is a level 4 NICU and one of two
regional cooling centres among eight hospitals with 30 000 annual
deliveries in the Southwest of England. Inclusion criteria for TH fol-
lowed the TOBY protocol [21]: in infants 36weeks with reduced
consciousness and A) at least one of the following: Apgar10min 5,
need for assisted ventilation 10 min after birth, pH <7.0 or base
excess (BE) 16 mmol/L within the first hour after birth; B) clinical
presentation of moderate (HIE-2) or severe encephalopathy (HIE-3);
or C) moderately or severely abnormal amplitude-integrated electro-
encephalography (aEEG) background voltage pattern within 6 h of
birth or aEEG-confirmed seizures lasting 3 min within 1 h with any
background pattern. All infants <6 h old who fulfilled these entry cri-
teria, including other comorbid diagnoses such as postnatal collapse,
were offered TH [22]. Twenty-two infants born 20142017 with
mild encephalopathy (HIE-1) were removed from the dataset. Infants
born between 01/01/2018 and 31/12/2019 were excluded from the
main analyses and are only presented in Fig. 1 (n = 57). Neurodeve-
lopmental outcome was not yet available for these infants, leaving
282 patients for the main analysis, of which 258 survived.
The Bristol TH protocol [23] includes starting passive cooling early
(<1 h) and routinely intubating cooled infants. aEEG was monitored
before and during TH until after rewarming. Infants received pre-
emptive morphine-sulphate with a loading dose of 50 mg/kg fol-
lowed by a continuous infusion rate of 20 mg/kg/h. The dose was
adjusted to clinical needs. In 28 patients additional opioids (25 fenta-
nyl-citrate, 3 remifentanil) were administered (boli or IV continuous
infusions). Pain was assessed by the bedside health professionals
using clinical experience, facial pain score [2] and heart rate changesanyl exposure during therapeutic hypothermia does not impair
clinm.2021.100892
Fig. 1. Cumulative SA mg/kg administered during the first week of life shows a monotonous increase over years. Additional data from surviving infants born in 20182019 (n = 57)
are included to show the progression of morphine and fentanyl use over time. N = 25 infants received additional fentanyl in 2007 to 2017, n = 23 received additional fentanyl in
2018 to 2019. Deceased infants are excluded from figure (n = 29).
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for anticonvulsant drugs was followed during the study period: phe-
nobarbital, phenytoin, clonazepam, lidocaine or midazolam [23].
At 1824 months of age, survivors were scheduled for follow-up
in the cooling programme with a senior neurodevelopmental physio-
therapist (SJ) for assessment of motor, cognition and language skills
with Bayley-3 Scales of Infant and Toddler Development 3rd edition
[24] (mean 100, standard deviation 15). Bayley-3 scores <85 in any
domain are defined as adverse outcome in this study. The examiner
was blinded to information on clinical treatment and results of inves-
tigations (e.g. MRI) at the time of examination. Scores <85 in any
domain are indicative of adverse outcome. Other clinical examination
and information at 2 years were undertaken for 29 infants without
Bayley-3 examination.
Data collection
We collected information on drugs administered up to the
eighth day of life. All authors had access to the data. Morphine-
sulphate doses were converted to morphine-base doses by a factor
of 0.853. Fentanyl-citrate doses were converted to fentanyl-base
by a factor of 0.673. We calculated the cumulative morphine dose
mg/kg administered as IV or bolus during the first week of life.
The cumulative SA dose was calculated by converting fentanyl
and remifentanil to morphine equipotent doses by a factor x40
and x80 respectively and added to the morphine dose. Cumulative
SA therefore includes all morphine, fentanyl and remifentanil
doses administered. We also collected muscle relaxants, inotropic
and anticonvulsant drugs and total duration of SA use and dura-
tion of intubation. As a marker of stress, mean HR was registered
during stable periods at the following intervals: 1824 h,
4248 h, 6672 h and 8490 h after commencing active cooling,
and at 1218 h after cooling was stopped. We have previously
shown that inotropic drugs increase HR, and that 2 boli of atro-
pine increase HR and morphine dose administered [25].
Statistics
In order to detect any potential confounders between recorded
variables, we performed a multivariate stepwise linear regressionPlease cite this article as: J.K. Gundersen et al., Morphine and fent
neurodevelopment, EClinicalMedicine (2021), https://doi.org/10.1016/j.e(SPSS Statistics v.26.0) with Bayley-3 scores (cognition, language or
motor) as dependent variable, and included the following indepen-
dent variables: cumulative SA dose, year of birth, duration of cardio-
pulmonary resuscitation (CPR) in minutes, assisted ventilation
(intubation or bagging) at 10 min, sex, being outborn, weight-centile,
Apgar at 10 min, worst pH and BE at<1 h, HIE-grade, worst aEEG pat-
tern at <6 h, number of inotropic drugs, number of anticonvulsant
drugs, lactate dehydrogenase at 72 h, time to lactate <5 mmol/l and
intubation duration. Variables in the final regression model were
included at significance level < 0.05. In every regression performed,
only 13 variables were significant; number of anticonvulsants used,
worst aEEG pattern at <6 h and lactate dehydrogenase at 72 h. All
cumulative SA doses >5500 mg/kg were set to 5500 mg/kg in the
regression analysis. Because the effect of SA on Bayley 3 scores may
be severity-dependent, we also conducted a stratified multivariate
linear regression. The worst aEEG pattern <6 h of age is the best early
outcome predictor among the entry criteria [27]. The study popula-
tion was stratified into three severity subgroups: mild (CNV, CNVsz,
DNV n = 109), moderate (BS n = 110) and severe (LV, FT n = 39). For
standardised comparison between survivors and deceased infants,
we compared the mean cumulative SA dose administered per hour
during SA administration using the two-sample Wilcoxon Mann-
Whitney test.
As above, to examine which clinical variables were associated
with cumulative SA dose, a multivariate stepwise linear regression
was conducted with cumulative SA dose as dependent variable, and
the listed independent variables. To detect a change over the study
period, univariate linear regression analysis was used with year as
the independent variable. The results present which variables
changed over time. Since the data were non-normally distributed, we
used non-parametric analysis with Wilcoxon Mann-Whitney to
detect significant differences in two-sample situations. Correlation
between two continuous variables was tested with Kendell’s correla-
tion coefficient. Ranges are given in either interquartile ranges or 95%
confidence intervals (CI). Figures and graphs were created in Graph-
Pad Prism v.8.0.3. Missing values were replaced in n subjects by using
the median value for the whole cohort regards Apgar10min (n = 10)
and intubation duration (n = 2). For the following variables we used
the median in the patients aEEG subgroup classification; LDH72h
(n = 10), pH (n = 1), hours when the plasma lactate value was reducedanyl exposure during therapeutic hypothermia does not impair
clinm.2021.100892
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median of those who received CPR (n = 1).
Role of the funding source
The funding source had no role in the study design, the data anal-
ysis or data interpretation.
Results
We included 282 infants born between 2007 and 2017 in the anal-
ysis. Table 1 displays the neonatal clinical characteristics. Twenty-
four infants died, 21 in the neonatal period and 3 at the ages of 6
months, 22 months and 8 years. The median (IQR) cumulative SA
dose was 1200 mg/kg (507, 2403), not significantly different from
survivors when the dose of received SA was standardised per hour,
median (IQR) 24.6 mg/kg/h (15.4, 34.5) in deceased vs 23.0 mg/kg/h
(15.5, 31.1), p = 0.66 in survivors.
Among the 258 survivors, 229 had Bayley-3 assessment at 1824
months. The remaining 29 were given a binary adverse or favourable
outcome based on clinical examination carried out locally or by col-
leagues in other regions at 2 years. With respect to binary outcome,
none were lost to follow-up, however, 29 were missing Bayley exam-
ination required for some analyses. Main clinical and biochemical
variables did not differ between infants given a binary score and
infants assessed with Bayley-3. Selected variables in infants withTable 1
Clinical characteristics for n = 282 infants, born 01/01/200731/12/2017.
Baseline characteristics 2007 to 2017 (n = 282)
Outborn, number (%) 159/282 (56.4)
Male, number (%) 159/282 (56.4)
Gestational age in weeks, median (IQR) 40.0 (38.3, 41.0)
CPR at birth, number (%) 103/282 (36.5)
Duration (min) of CPR, median (IQR) 0.0 (0.0, 2.3)
Needing ventilation (intubated or bagged) at 10 min,
number (%)
222/282 (78.7)
Birth weight in grams, median (IQR) 3361 (2983, 3780)
Apgar 10 min, median (IQR) 6 (4, 8)
Apgar 10 min 5, number (%) 105/282 (37.2)
Worst pH within 1 h of birth, median (IQR) 6.96 (6.85, 7.09)
Worst pH within 1 hour of birth <7.0, number (%) 156/282 (55.3)
Worst base excess within 1 h of birth, median (IQR) 16.0 (12.6, 20.5)
Worst base excess within 1 h of birth 16 mmol/L,
number (%)
138/282 (48.9)
Normal aEEG voltage*, number (%) 9/282 (3.2)
Moderately abnormal aEEG voltage*, number (%) 219/282 (77.7)
Severely abnormal aEEG voltage*, number (%) 54/282 (19.1)
HIE grade 2, number (%) 186/282 (66.0)
HIE grade 3, number (%) 96/282 (34.0)
Death, number (%) 24/282 (8.5)
Mechanical ventilation and SA during 1st week of
life in survivors (n = 258)
Intubation duration in hours, median (IQR) 96 (86, 112)
Duration (h) end of active cooling to extubation,
median (IQR)
23 (14, 35)
Duration (h) end of SA delivery to extubation, median
(IQR)
7 (2, 16)
Sedation duration, median (IQR) 86 (79, 97)
Cumulative morphinemg/kg, median (IQR) 2052 (1291, 2628)
Additional fentanyl or remifentanil, number (%) 28/258 (10.9)
Bolus, number (%) 14/28 (50.0)
Continuous infusion, number (%) 14/28 (50.0)
Cumulative non-converted fentanyl (mg/kg) median
(IQR)
7.5 (3.0, 126.1)
Cumulative converted SAmg/kg, median (IQR) 2121 (1343, 2741)
*Voltage classification of aEEG for entry-criteria (pattern classification groups).
Normal aEEG voltage: Continuous Normal Voltage (CNV). Moderately abnormal
aEEG voltage: continuous normal voltage with seizures (CNVsz) or Discontinuous
Normal Voltage (DNV), or Burst Suppression (BS).
Severely abnormal aEEG voltage: Low Voltage (LV) or Flat Trace (FT).
Please cite this article as: J.K. Gundersen et al., Morphine and fent
neurodevelopment, EClinicalMedicine (2021), https://doi.org/10.1016/j.ebinary score versus Bayley-3 assessment respectively are: worst
pH < 1 h (p = 0.86), aEEG at entry (p = 0.88), cumulative SA (p = 0.19,
median (IQR) 2013 mg/kg (1280, 2340) versus 2158 mg/kg (1350,
2771)) and HIE-grade (p = 0.16, 56% HIE-2 versus 69% HIE-2). The
mean Bayley-3 scores for cognition, language and motor have stayed
unchanged over the 11 year duration of this study as shown by linear
regression analysis with year as the independent variable (all p-
values > 0.6).
The cumulative SA dose administered during the first week of life
was median (IQR) 2121 mg/kg (1343, 2741), with an annual monoto-
nous increase of coefficient +216 mg/kg/year, 95%CI (160, 272) from
2007 to 2017 (Fig. 1). The duration of SA administration, median
(IQR) 86 h (79, 97), remained unchanged across the study period:
coefficient +0.036 h/year, 95%CI (0.916, 0.988). The use of fentanyl
(n = 25) and remifentanil (n = 3) has increased over the last 4 years
(Fig. 1), from nearly no use up to 2014, to 40% of infants receiving
additional sedatives by 2017. These infants (n = 28), received median
(IQR) 1580 mg/kg morphine (958, 2536), with total median (IQR) SA
dose 3045 mg/kg (2029, 4574). There was no difference between the
morphine-only group and the group receiving other opioids in their
pH at <1 h (p = 0.12, respectively median (IQR) 6.97 (6.86, 7.09) ver-
sus 7.0 (6.9, 7.12)), aEEG background pattern at <6 h (Fig. 2, p = 0.11),
heart rate (HR) during cooling (p = 0.56), intubation duration
(p = 0.95) or SA duration (p = 0.55). However, infants receiving fenta-
nyl also received fewer anticonvulsive drugs (Fig. 3, p = 0.006) and
had milder HIE-grade (p = 0.03). Fig. 4 illustrates the temporal rela-
tion between active cooling, rewarming, intubation and continuous
IV morphine infusion during the first week of life. Eighty-seven% of
infants were mechanically ventilated for the entire duration of TH,
with median intubation duration of 95 h (84, 112), which is strongly
correlated with sedation duration (p < 0.001). Intubation duration
did not change over time. We did not observe the expected adverse
effect of high SA doses like delayed extubation, neonatal abstinence
syndrome (NAS) or urine retention.
We examined which clinical factors were associated with the
cumulative SA dose administered. Among the early clinical variables
(<6 h of age), the cumulative SA dose was only significantly associ-
ated with year of birth (coefficient +229 mg/kg/year, 95%CI (170,
288)). aEEG pattern <6 h of age was not associated with cumulative
SA dose (p = 0.5, Fig. 2). After allowing clinical variables obtained after
6 h of age into the regression analysis, year of birth was still the mostFig. 2. Cumulative SA dose (mg/kg) distribution for each aEEG pattern classification
category. Black line shows the median in each group. This distribution shows that
cumulative SA dose is not associated with aEEG severity.
anyl exposure during therapeutic hypothermia does not impair
clinm.2021.100892
Fig. 3. Data from 2007 to 2017. Infants with clinical or electrical seizures received from
1 to 5 number of different anticonvulsive drugs of which phenobarbital, clonazepam
and midazolam also have a sedative effect. Infants with more anticonvulsants received
less morphine (530 mg/kg per anticonvulsant drug, p < 0001).The black line shows
the median. Multiple administrations of the same drug counts as one drug.
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administered (Fig. 3) (coefficient 372 mg/kg/drug, 95%CI (525,
219)) and longer intubation duration (coefficient +6.66 mg/kg/h,
95%CI (1.8, 11.5)).
Stepwise linear regression analysis of each Bayley-3 domain as the
dependent variable was conducted in the entire cohort and in each of
the 3 aEEG-severity subgroups. There was no significant association
between cumulative SA dose and Bayley-3 scores in any of the Bay-
ley-3 domains (Fig. 5). The strongest clinical predictors of adverse
Bayley-3 scores in our cohort are further explored in a logistic regres-
sion model presented in our reference [26].Fig. 4. Timeline over the first week of life shows scatter plot of cumulative continuous IV mo
fentanyl or remifentanil. Lines show median and interquartile range.
Please cite this article as: J.K. Gundersen et al., Morphine and fent
neurodevelopment, EClinicalMedicine (2021), https://doi.org/10.1016/j.eDiscussion
The long-term effects of morphine exposure in term-born cooled
asphyxiated infants are unknown. Our hypothesis was that higher
cumulative SA doses during the first week of life could impair cogni-
tive ability and language in infancy. We found no evidence for an
adverse dose-dependent effect of morphine and fentanyl exposure
on Bayley-3 scores in cognition, language or motor function at 1824
months of age. The infants who died did not receive more opioids
than the survivors and there was no overdosing of deceased infants.
We had a concern for confounding regarding the less severe infants
with milder encephalopathy and potentially stronger clinical expres-
sion of discomfort, thereby receiving higher cumulative SA doses.
These are also the infants with expected good outcome. To reduce
this confounding, we included known severity variables and outcome
predictors, such as early aEEG, number of anticonvulsant drugs
needed and LDH at 72 h. Because the coefficient for cumulative SA
dose in this multivariate linear regression alternated between being
positive and negative, this indicated that even if such confounders
were to be present, their effect would be small.
Recently published studies in cooled asphyxiated infants support
our general findings. In a secondary retrospective analysis of the RCT
NICHD-trial [28] from 2005, infants were treated with normothermia
or TH. SA was collected as a categorical variable without dose or
duration and they report no effect of SA on Bayley-2 MDI-scores at
1824 months. Similarly, in the secondary analysis of the MARBLE
study no effect of similar categorically collected SA on Bayley-3
scores at 2024 months was reported [29].
In our study, we collected hourly data of ventilation and all drug
administration for seven days and not just the duration of cooling
and rewarming to include infants with delayed extubation due to dis-
ease severity.
Sedation was stopped at a median of 7 h after rewarming and
infants were extubated at a median of 9 h after end of sedation. There
was no relationship between cumulative SA-dose and time at extuba-
tion as shown in Fig. 4.
Longer intubation durations required longer SA duration, and
mechanical ventilation is one of the main reasons for delivering SA
during cooling. Infants with seizures who received sedative anticon-
vulsant drugs, received lower cumulative SA dose. Seizures are com-
mon in an asphyxia cohort; phenobarbital was given to 60%,
clonazepam to 14% and midazolam to 5% and the sedative effect ofrphine infusion administered each day, excluding deceased infants and those receiving
anyl exposure during therapeutic hypothermia does not impair
clinm.2021.100892
Fig. 5. Individual Bayley-3 scores at 1824 months in cognition, language and motor
domain. The black dotted line shows the predicted mean of the score (100), and the red
dotted line shows the cut off value (85) for adverse outcome used. Scores below the
lowest testable value were obtained by ranking the raw scores in each domain [26].
Fig. 6. Estimated median morphine plasma concentrations at steady-state for various
hourly infusion rates, for birthweight=3500 g using clearance (L/h) = 0.765 as reported
by Frymoyer [17]. A proposed therapeutic target plasma concentration is 10100 mg/L
(light blue bars). Periodically, infusion rates as high as 60 mg/kg/h were given in our
cohort (medium blue bars).
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6 J.K. Gundersen et al. / EClinicalMedicine 00 (2021) 100892these drugs are likely to reduce the need for SA. Very severely
asphyxiated infants are more encephalopathic, expressing less clini-
cal signs of stress, discomfort and pain and therefore need less SA. APlease cite this article as: J.K. Gundersen et al., Morphine and fent
neurodevelopment, EClinicalMedicine (2021), https://doi.org/10.1016/j.esubgroup of the patients were paralysed and needing paralysis
resulted in higher SA doses. This is due to clinical practice in para-
lysed patients and adds to the variability in SA administration.
The choice of morphine only or morphine and fentanyl as the opi-
oid used reflects a change in practice among medical staff toward the
end of the recruitment-period. There was no change in the protocol
sedation guidelines. Morphine safety-data are available from a few
studies which report plasma levels in relation to outcome. Our most
recent SA data on surviving infants born in 20182019 (n = 57) show
that the use of fentanyl (n = 23) in addition to morphine is continuing
(Fig. 1) and in 50% of the patients. Infants who received additional
fentanyl or remifentanil are evenly distributed among the range of
aEEG severity patterns (Fig. 2) and Bayley 3 scores in all domains
(Fig. 5).
In a prospective pharmacokinetic study of 20 term-born infants,
morphine was administered during TH for SA, plasma concentrations
were measured to create a simulated pharmacokinetic model. At an
infusion rate of 5 mg/kg/h, 81% of neonates achieved target morphine
concentrations of 1040 ng/ml. At an infusion rate of 10 mg/kg/h,
54% were in the target zone, while 46% had morphine concentrations
>40 ng/ml [17]. Because the infusion rates in our cohort often are
much higher, we extrapolated from the Frymoyer et al. pharmacoki-
netic model the steady-state morphine plasma concentrations for
infusion rates of 30 to 60mg/kg/h (Fig. 6). The predicted median mor-
phine concentrations ranged from almost 120 to 240 ng/ml, which is
much higher than the proposed target concentration. If this was true,
it is surprising we found no delay in extubation after weaning of SA.
It is unknown whether the reduced receptor affinity seen experimen-
tally during cooling [20] is translatable to humans.
Even though we found no effect on neurodevelopmental outcome
at 1824 months, the increasing use of morphine and fentanyl dur-
ing TH is concerning. It is still unknown whether opioids may impair
higher order cognitive functions later in childhood (executive func-
tions e.g. goal orientation, adaptive behaviour, etc.) which can be
tested at early school age. In a RCT of preterm infants (median
29 GW) randomized to SA with morphine 100 mg/kg + 10 mg/kg/h
(n = 73), or placebo (n = 77), no effect on intelligence, visual motor
integration or behaviour was found at 5-year follow up [30]. A signifi-
cant negative effect was found in a subtest of the intelligence test,
which assessed response inhibition (a component of executive func-
tions), however this was negated when retested at 89-years [31].anyl exposure during therapeutic hypothermia does not impair
clinm.2021.100892
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J.K. Gundersen et al. / EClinicalMedicine 00 (2021) 100892 7In our study, exact doses of morphine, fentanyl and remifentanil
were collected for 7 days. This is a unique database because of
increasing SA use over the years. The limitations of our study are that
we were unable to measure the morphine plasma concentrations
during TH and that we did not have a reliable pain score for cooled
infants as all facial pain scores were recorded as zero. From 2014, the
patients being offered TH also incorrectly included 22 with HIE-1. We
have removed these from the analysis so all children fulfilled the
TOBY entry criteria. We presupposed that the cumulative SA dose
most precisely reflects drug exposure, as it incorporates both dosage
and duration. However, it is unknown whether the peak plasma con-
centration or the plasma concentration over time (area under the
curve) is the most toxic for the developing brain. It is also an unan-
swered question whether cooling reduces opioid receptor binding
and hence drug potency. Further research with long term follow-up
is necessary before concluding that high opioid doses are safe for
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